Newsbenzinga
Alterity Therapeutics Secures Key US Patent for Lead Asset
· Published
Article summary
Alterity Therapeutics secured a USPTO patent for ATH434, extending market protection for its neurodegenerative drug candidate to 2045.
An excerpt from the original article.
Comments —
Loading comments…